384336-73-6

Usage

InChI:InChI=1/C13H19N5/c1-9-3-5-14-7-11(9)18(2)13-10-4-6-15-12(10)16-8-17-13/h4,6,8-9,11,14H,3,5,7H2,1-2H3,(H,15,16,17)/t9-,11+/m0/s1

Upstream product

• 1228879-37-5 N,4-dimethyl-1-(phenylmethyl)-3-piperidineamine bishydrochloride 
• 384338-23-2 (1-benzyl-4-methyl-piperidin-3-yl)-methyl-amine 
• 32018-96-5 1-benzyl-4-methyl-piperidin-3-one 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 384337-90-0 methyl(1-phenylmethyl-4-methylpiperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine 

Downstream Products

• 540737-29-9 Tofacitinib citrate 
• 1259404-17-5 tasocitinib 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 

Relevant academic research and scientific papers

EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE

Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6. Salification of intermediate II to give tofacitinib monocitrate (I)

PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING DRY EYE DISORDERS

Ophthalmic compositions comprising Inhibitors of Janus kinase-3 (“Jak3”) are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

COMBINATION THERAPIES FOR RHEUMATOID ARTHRITIS

This disclosure relates to pharmaceutical combination therapies for the treatment or prevention of arthritis, such as rheumatoid arthritis, in a human comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and at least one anti-arthritic agent or a pharmaceutically acceptable salt thereof. This disclosure also relates to certain methods for treating or preventing arthritis, such as rheumatoid arthritis, in a human comprising co-administering to a human a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and at least one anti-arthritic agent or a pharmaceutically acceptable salt thereof.

METHOD OF TREATMENT OF TRANSPLANT REJECTION

A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula (I) wherein R1, R2 and R3 are as defined above.

Method of treatment of atherosclerosis

A method of treating or preventing atherosclerosis comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.

Method of treatment of transplant rejection

A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.

Pyrrolo[2,3-d]pyrimidine compounds

A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

Pyrrolo[2,3-d]pyrimidine compounds

A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.